New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTWCIC, INCY, TRVN, COV, ITCI, GOLD, KLIC, EPE, NUTR, IVAC, APL, RTEC, LJPC, HELIOn The Fly: Analyst Initiation Summary
Atlas Pipeline Partners (APL) initiated with a Hold at Deutsche Bank... CHC Group (HELI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Overweight at JPMorgan... Intevac (IVAC) initiated with a Neutral at B. Riley... Kulicke & Soffa (KLIC) initiated with a Buy at B. Riley... La Jolla Pharmaceutical (LJPC) initiated with an Outperform at Wedbush... Nutraceutical (NUTR) initiated with an Outperform at Imperial Capital... Randgold Resources (GOLD) initiated with a Buy at UBS... Rudolph Technologies (RTEC) initiated with a Buy at B. Riley... Trevena (TRVN) initiated with an Outperform at JMP Securities... WCI Communities (WCIC) reinstated with an Outperform at Credit Suisse... Covidien (COV) initiated with a Buy at CRT Capital... Incyte (INCY) coverage assumed with a Buy at BofA/Merrill... Intra-Cellular (ITCI) initiated with an Outperform at Cowen.
News For APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
10:58 EDTLJPCDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
09:58 EDTTRVNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Alibaba (BABA) initiated with an Outperform at Bernstein... Alkermes (ALKS) initiated with an Overweight at Barclays... Burlington Stores (BURL) initiated with an Outperform at FBR Capital... Crocs (CROX) initiated with a Neutral at B. Riley... Darling (DAR) initiated with a Buy at Roth Capital... Dynegy (DYN) initiated with an Outperform at RBC Capital... Esperion (ESPR) initiated with an Overweight at Barclays... Five Below (FIVE) initiated with a Market Perform at FBR Capital... Intercept (ICPT) initiated with an Overweight, $450 target at Barclays... Johnson Matthey (JMPLY) initiated with a Buy at Jefferies... Nike (NKE) initiated with a Buy at Jefferies... RTI Surgical (RTIX) initiated with a Buy at Sidoti... TeleNav (TNAV) initiated with an Outperform at Northland... Trevena (TRVN) initiated with an Equal Weight at Barclays... Vectrus (VEC) initiated with a Hold at Stifel.
05:41 EDTTRVNTrevena initiated with an Equal Weight at Barclays
Subscribe for More Information
May 20, 2015
07:18 EDTIVACIntevac management to meet with Needham
Meeting to be held in Boston on May 20 hosted by Needham.
May 19, 2015
07:22 EDTINCYIncyte has a conference call hosted by JPMorgan
Subscribe for More Information
May 18, 2015
07:19 EDTITCIIntra-Cellular announces further analyses of Phase 2 clinical trial of ITI-007
Subscribe for More Information
May 15, 2015
09:56 EDTLJPCTang Capital increases stake in La Jolla Pharmaceutical to 15.3%
Subscribe for More Information
May 14, 2015
08:50 EDTINCYIncyte data promising, says SunTrust
SunTrust believes that the data for Incyte's JAK1/PI3K combination in NHL and HL is promising. The firm says that the combo shows early signs of activity in B cell malignancies. It keeps a $120 price target and Buy rating on the shares.
07:08 EDTTRVNTrevena announces presentation of preclinical data for TRV250 program
Trevena announced that data highlighting its preclinical TRV250 program will be presented in an oral presentation at the International Headache Congress being held in Valencia, Spain, May 14-17, 2015. “Our preclinical data suggests TRV250 may safely activate the delta receptor in the central nervous system, and could become a first-in-class therapy for migraine and other CNS disorders,” said Maxine Gowen, Ph.D., CEO. “TRV250 is Trevena’s fourth biased ligand product candidate in development, which highlights the productivity of our platform in delivering differentiated new chemical entities targeting important unmet clinical needs.” Aimee Crombie, Ph.D., director of chemistry, will give an oral presentation entitled “TRV250: a novel biased ligand at the delta receptor for the potential treatment of migraine” in a session scheduled for 10:00 - 11:00 a.m. local time on Friday, May 15. The presentation will describe the preclinical profile of TRV250 and its actions at the delta opioid receptor, a CNS target with potential benefits in migraine and other CNS disorders. Previous efforts to develop selective delta receptor ligand drugs have been hindered by seizure risk which, in Trevena studies, was associated with delta receptor signals mediated by the scaffold protein β-arrestin2. Compared to previously described ligands, TRV250 elicits markedly reduced β-arrestin2 recruitment to the delta receptor. TRV250 is active in models of acute and chronic migraine as well as models of depression, anxiety, and pain, including pain associated with central sensitization. TRV250 displayed very broad safety margins in multiple preclinical species, and is not expected to have addiction or abuse liability associated with mu-opioid agonists like morphine and oxycodone.
May 13, 2015
07:10 EDTIVACB. Riley to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use